UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Adipokines and insulin resistance

Molecular medicine (Cambridge, Mass.), 2008-11, Vol.14 (11-12), p.741-751

2008

Volltextzugriff (PDF)

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

Diabetes & vascular disease research, 2015-03, Vol.12 (2), p.90-100

2015

Volltextzugriff (PDF)

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes

Clinical therapeutics, 2016-06, Vol.38 (6), p.1299-1313

2016

Volltextzugriff (PDF)

The role of machine learning in clinical research: transforming the future of evidence generation

Trials, 2021-08, Vol.22 (1), p.537-537, Article 537

2021

Volltextzugriff (PDF)

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

Diabetes care, 2017-09, Vol.40 (9), p.1144-1151

2017

Volltextzugriff (PDF)

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

Diabetologia, 2014-12, Vol.57 (12), p.2599-2602

2014

Volltextzugriff (PDF)

Inclusion and diversity in clinical trials: Actionable steps to drive lasting change

Contemporary clinical trials, 2022-05, Vol.116, p.106740-106740, Article 106740

2022

Volltextzugriff (PDF)

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes

Kidney international, 2014-11, Vol.86 (5), p.1057-1058

2014

Volltextzugriff (PDF)

Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

Journal of the American College of Cardiology, 2018-01, Vol.71 (3), p.364-367

2018

Volltextzugriff (PDF)

Expression of Human Chemerin Induces Insulin Resistance in the Skeletal Muscle but Does Not Affect Weight, Lipid Levels, and Atherosclerosis in LDL Receptor Knockout Mice on High-Fat Diet

Diabetes (New York, N.Y.), 2010-11, Vol.59 (11), p.2898-2903

2010

Volltextzugriff (PDF)

Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers

Clinical therapeutics, 2015-07, Vol.37 (7), p.1503-1516

2015

Volltextzugriff (PDF)

EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK

Journal of the American College of Cardiology, 2016-04, Vol.67 (13), p.1869-1869

2016

Volltextzugriff (PDF)

ARE THE CARDIOVASCULAR RISK REDUCTIONS SEEN WITH EMPAGLIFLOZIN IN THE EMPA-REG OUTCOME TRIAL EXPLAINED BY CONVENTIONAL CARDIOVASCULAR RISK FACTORS?

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.1809-1809

2017

Volltextzugriff (PDF)

Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase

Circulation (New York, N.Y.), 2003-10, Vol.108 (17), p.2121-2126

2003

Volltextzugriff (PDF)

Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo

The Journal of clinical investigation, 2003-02, Vol.111 (3), p.357-362

2003

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes

Diabetes therapy, 2016-09, Vol.7 (3), p.455-471

2016

Volltextzugriff (PDF)

Erratum. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes care 2015;38:394-402

Diabetes care, 2015-06, Vol.38 (6), p.1173-1173

2015

Volltextzugriff (PDF)

Erratum. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes care 2015;38:384-393

Diabetes care, 2015-06, Vol.38 (6), p.1173-1173

2015

Volltextzugriff (PDF)

Correction to: The role of machine learning in clinical research: transforming the future of evidence generation

Trials, 2021-09, Vol.22 (1), p.593-593, Article 593

2021

Volltextzugriff (PDF)

Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

Diabetologia, 2017-06, Vol.60 (6), p.1159-1160

2017

Volltextzugriff (PDF)

Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot

Blockchain in healthcare today, 2021, Vol.4

2021

Volltextzugriff (PDF)

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers

International journal of clinical pharmacology and therapeutics, 2013-02, Vol.51 (2), p.132

2013

Volltextzugriff (PDF)

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

The Journal of clinical investigation, 2014-04, Vol.124 (4), p.1868-1868

2014

Volltextzugriff (PDF)

Predictions for Blockchain in 2020

Blockchain in healthcare today, 2020, Vol.3

2020

Volltextzugriff (PDF)

Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study

Diabetes therapy, 2015-12, Vol.6 (4), p.635-642

2015

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(56)
Dissertationen
(1)

Sprache

Englisch
(56)
Japanisch
(12)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Adipokines and insulin resistance

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes

The role of machine learning in clinical research: transforming the future of evidence generation

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

Inclusion and diversity in clinical trials: Actionable steps to drive lasting change

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes

Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

Expression of Human Chemerin Induces Insulin Resistance in the Skeletal Muscle but Does Not Affect Weight, Lipid Levels, and Atherosclerosis in LDL Receptor Knockout Mice on High-Fat Diet

Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers

EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK

ARE THE CARDIOVASCULAR RISK REDUCTIONS SEEN WITH EMPAGLIFLOZIN IN THE EMPA-REG OUTCOME TRIAL EXPLAINED BY CONVENTIONAL CARDIOVASCULAR RISK FACTORS?

Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase

Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo

Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes

Erratum. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes care 2015;38:394-402

Erratum. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes care 2015;38:384-393

Correction to: The role of machine learning in clinical research: transforming the future of evidence generation

Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration

Leveraging Blockchain Technology for Informed Consent Process and Patient Engagement in a Clinical Trial Pilot

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Predictions for Blockchain in 2020

Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study

Aktive Filter

Suchergebnisse filtern